Nutex Health under scrutiny for alleged deceptive billing scheme.

• Nutex Health under legal scrutiny for deceptive billing strategy. • Class-action lawsuit alleges Nutex collaborated with HaloMD. • Third-party billing firm allegedly submitted ineligible insurance claims. • Misleading shareholders and triggering substantial losses. • Hagens Berman urges Nutex investors to submit losses. • Class Period: Aug. 8, 2024 – Aug. 14, 2025. • Lead Plaintiff Deadline: Oct. 21, 2025.

Nutex Health Inc. (NASDAQ: NUTX), a publicly traded operator of micro-hospitals and healthcare facilities, is under legal scrutiny following a class-action lawsuit that accuses the company of orchestrating a deceptive billing strategy to artificially boost its financial results. The litigation, filed in a Texas federal court, alleges that Nutex collaborated with third-party billing firm HaloMD to submit ineligible insurance claims, misleading shareholders and triggering substantial losses.

The class-action suit, led by law firm Hagens Berman Sobol Shapiro LLP, claims that Nutex and HaloMD engaged in a systematic effort to exploit the insurance arbitration process. The companies are accused of submitting thousands of questionable claims, falsely certifying their validity to extract outsized reimbursements. These arbitration-driven revenues, the plaintiffs argue, were central to Nutex's reported financial performance but lacked long-term viability.

The lawsuit also asserts that Nutex misrepresented its progress in addressing internal control deficiencies. Specifically, the company is accused of misclassifying stock-based compensation obligations—treating them as equity rather than liabilities—thereby distorting its financial position. The situation escalated on Aug. 21, when Nutex disclosed in a Form 8-K that its Audit Committee had determined certain prior financial statements required restatement.

The allegations gained traction after activist short-seller Blue Orca Capital published a report on July 22, 2025, accusing HaloMD of orchestrating a "fraudulent scheme" to siphon millions from insurers. The report cited lawsuits filed by Anthem and Blue Cross Blue Shield affiliates, which claimed HaloMD overwhelmed the arbitration system with invalid claims. Blue Orca warned that Nutex's reliance on arbitration reimbursements posed a significant risk, suggesting the company's stock could collapse to penny-stock levels.

Hagens Berman urges Nutex investors who suffered substantial losses to submit their losses now. The class period for the lawsuit is Aug. 8, 2024 – Aug. 14, 2025, with a lead plaintiff deadline of Oct. 21, 2025. Investors can contact the firm at 844-916-0895 for more information.

References:
[1] https://www.prnewswire.com/news-releases/nutex-health-nutx-faces-investor-lawsuit-over-alleged-revenue-inflation-scheme---hagens-berman-302546193.html
[2] https://www.globenewswire.com/news-release/2025/09/03/3143945/683/en/DEADLINE-ALERT-Faruqi-Faruqi-LLP-Investigates-Claims-on-Behalf-of-Investors-of-Nutex-Health.html